New cancer drug trial halted after early testing
NCT ID NCT04260802
Summary
This early-stage study tested a new drug called OC-001, both by itself and combined with an existing immunotherapy drug, in people with various advanced cancers that had stopped responding to standard treatments. The main goal was to check the safety of the drug and see how the body processes it. The study was terminated and did not move to later phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 0A9, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Jewish General Hospital - Clinical Research Unit
Montreal, Quebec, H3T 1E2, Canada
-
Ottawa Hospital Cancer Centre (OHRI)
Ottawa, Ontario, Canada
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2C1, Canada
Conditions
Explore the condition pages connected to this study.